Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for ELGX
6.87
+0.12 (1.78%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.68 - 6.88
52 week 6.22 - 14.49
Open 6.77
Vol / Avg. 1.09M/2.28M
Mkt cap 588.65M
P/E     -
Div/yield     -
EPS -1.85
Shares 82.69M
Beta 0.95
Inst. own 116%
Feb 20, 2017
Q4 2016 Endologix Inc Earnings Release (Estimated) - 12:00AM EST - Add to calendar
Dec 13, 2016
Endologix Inc at Guggenheim Boston Healthcare Conference Add to calendar
Nov 30, 2016
Endologix Inc at Piper Jaffray Healthcare Conference
Nov 17, 2016
Endologix Inc 2016 Investor Meeting
Nov 17, 2016
Endologix Inc at Canaccord Genuity Med Tech Conference
Nov 15, 2016
Endologix Inc at Stifel Healthcare Conference
Nov 9, 2016
Endologix Inc at Stephens Fall Investor Conference
Nov 1, 2016
Q3 2016 Endologix Inc Earnings Call
Nov 1, 2016
Q3 2016 Endologix Inc Earnings Release
Sep 14, 2016
Endologix Inc at Credit Suisse Small & Mid Cap Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -29.25% -32.83%
Operating margin -21.55% -34.51%
EBITD margin - -27.30%
Return on average assets -15.91% -17.41%
Return on average equity -44.02% -44.34%
Employees 619 -
CDP Score - -

Address

2 Musick
IRVINE, CA 92618-1631
United States - Map
+1-949-5957200 (Phone)
+1-949-6999622 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Officers and directors

John D. McDermott Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 54
Bio & Compensation  - Reuters
Vaseem Mahboob Chief Financial Officer, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Michael V. Chobotov Ph.D. Chief Technology Officer
Age: 55
Bio & Compensation  - Reuters
David M. Jennings Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Amanda L. DePalma Vice President - Global Marketing
Age: 44
Bio & Compensation  - Reuters
Jose A. Lima Vice President - Quality
Age: 50
Bio & Compensation  - Reuters
Shari L. O'Quinn Vice President - Regulatory and Quality Affairs
Age: 43
Bio & Compensation  - Reuters
James E. Machek Vice President - Research and Development, Manufacturing, Irvine
Age: 59
Bio & Compensation  - Reuters
Joseph A. DeJohn General Manager - Asia/Pacific and Latin America
Age: 55
Bio & Compensation  - Reuters